 Enanta Pharmaceuticals Inc NASDAQ: ENTA has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. The data were presented at the International Society for Influenza and Other Respiratory Virus Diseases ISIRVWorld Health Organization WHO Virtual Conference 2021. 